

ASO-Based Therapeutics Targeting ATX for Pulmonary Fibrosis

Sookmyung Women's University



SOOKMYUNG
WOMEN'S UNIVERSITY

RESPIRATORY	Hit
Product Type	Gene/Cell Therapy & Nucleic acids
Indication	Pulmonary fibrosis
Target	Autotaxin
MoA(Mechanism of Action)	ASO mediated <i>Autotaxin</i> RNA degradation
Competitiveness	The therapeutic is a first-in-class antisense oligonucleotide (ASO) that specifically targets Autotaxin (ATX), a key enzyme involved in lysophosphatidic acid (LPA) production and fibrosis signaling. Compared to small molecule ATX inhibitors (e.g., Ziritaxestat), the ASO provides higher target specificity at the mRNA level, reduced off-target effects, and potential for longer duration of action with lower systemic exposure.
Development Stage	Hit
Route of Administration	Inhalation (dry powder or solution)

Any unauthorized distribution or reproduction of this material is strictly prohibited.